Resistance gene-guided genome mining reveals the roseopurpurins as inhibitors of cyclin-dependent kinases.


Journal

Proceedings of the National Academy of Sciences of the United States of America
ISSN: 1091-6490
Titre abrégé: Proc Natl Acad Sci U S A
Pays: United States
ID NLM: 7505876

Informations de publication

Date de publication:
28 Nov 2023
Historique:
medline: 22 11 2023
pubmed: 20 11 2023
entrez: 20 11 2023
Statut: ppublish

Résumé

With the significant increase in the availability of microbial genome sequences in recent years, resistance gene-guided genome mining has emerged as a powerful approach for identifying natural products with specific bioactivities. Here, we present the use of this approach to reveal the roseopurpurins as potent inhibitors of cyclin-dependent kinases (CDKs), a class of cell cycle regulators implicated in multiple cancers. We identified a biosynthetic gene cluster (BGC) with a putative resistance gene with homology to human CDK2. Using targeted gene disruption and transcription factor overexpression in

Identifiants

pubmed: 37983497
doi: 10.1073/pnas.2310522120
pmc: PMC10691236
doi:

Substances chimiques

Cyclin-Dependent Kinases EC 2.7.11.22
Cyclin-Dependent Kinase 2 EC 2.7.11.22
Cyclins 0
Enzyme Inhibitors 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e2310522120

Déclaration de conflit d'intérêts

Competing interests statement:K.L.D, B.P., N.L., D.M., A.C., Y.-M.C., L.H., M.N., J.P., H.L.N. and C.J.B.H. are all shareholders in Hexagon Bio.

Références

Metab Eng Commun. 2015 Sep 25;2:117-123
pubmed: 34150514
Fitoterapia. 2020 Jun;143:104561
pubmed: 32199959
Org Lett. 2017 Jul 7;19(13):3560-3563
pubmed: 28605916
Chem Sci. 2020 Aug 19;11(35):9554-9562
pubmed: 34094220
J Am Chem Soc. 2021 Apr 28;143(16):6043-6047
pubmed: 33857369
Science. 1999 May 21;284(5418):1368-72
pubmed: 10334994
Nat Commun. 2020 Jun 2;11(1):2743
pubmed: 32488087
Nat Prod Rep. 2020 Jan 29;37(1):6-16
pubmed: 31033969
J Biol Chem. 2003 May 16;278(20):18485-90
pubmed: 12624112
Org Lett. 2016 Sep 2;18(17):4340-3
pubmed: 27537356
Acta Crystallogr D Biol Crystallogr. 2010 Feb;66(Pt 2):125-32
pubmed: 20124692
Nucleic Acids Res. 2005 Apr 22;33(7):2302-9
pubmed: 15849316
Nat Chem Biol. 2007 Apr;3(4):213-7
pubmed: 17369821
Org Lett. 2016 Mar 18;18(6):1366-9
pubmed: 26954888
Nucleic Acids Res. 2021 Jul 2;49(W1):W29-W35
pubmed: 33978755
Essays Biochem. 2017 Nov 8;61(5):439-452
pubmed: 29118092
Acta Crystallogr D Biol Crystallogr. 2011 Apr;67(Pt 4):235-42
pubmed: 21460441
Proc Natl Acad Sci U S A. 2006 Mar 14;103(11):4234-9
pubmed: 16537514
Chem Biol. 2012 Aug 24;19(8):1049-59
pubmed: 22921072
Int J Mol Sci. 2020 Mar 13;21(6):
pubmed: 32183020
Breast Cancer Res. 2009;11(5):R77
pubmed: 19874578
Science. 2015 May 22;348(6237):921-5
pubmed: 25999509
Nat Chem Biol. 2015 Sep;11(9):671-7
pubmed: 26284674
J Am Chem Soc. 2022 Oct 26;144(42):19225-19230
pubmed: 36223511
Nat Rev Drug Discov. 2015 Feb;14(2):130-46
pubmed: 25633797
Sci Rep. 2020 Oct 28;10(1):18489
pubmed: 33116269
Nature. 2018 Jul;559(7714):415-418
pubmed: 29995859
Nat Prod Rep. 2012 Mar;29(3):392-403
pubmed: 22231144
Genome Biol. 2014;15(6):122
pubmed: 25180339
Invest New Drugs. 1999;17(3):313-20
pubmed: 10665481
Nat Rev Cancer. 2009 Jan;9(1):28-39
pubmed: 19104514
PLoS Genet. 2013 Jun;9(6):e1003496
pubmed: 23818858
ACS Chem Biol. 2013 Nov 15;8(11):2360-5
pubmed: 24007471
Nucleic Acids Res. 2005 Jan 1;33(Database issue):D476-80
pubmed: 15608241
Acta Crystallogr D Biol Crystallogr. 2004 Dec;60(Pt 12 Pt 1):2126-32
pubmed: 15572765
J Biomol Struct Dyn. 2022 Oct;40(17):7693-7701
pubmed: 33749525
J Antibiot (Tokyo). 2020 Jul;73(7):475-479
pubmed: 32139880
Acta Crystallogr D Biol Crystallogr. 2011 Apr;67(Pt 4):293-302
pubmed: 21460447
Mol Cancer Ther. 2010 Aug;9(8):2344-53
pubmed: 20663931
Acta Crystallogr D Biol Crystallogr. 2013 Jul;69(Pt 7):1204-14
pubmed: 23793146
Oncogene. 1993 Sep;8(9):2425-32
pubmed: 8395680
J Biomol Struct Dyn. 2020 Oct;38(17):5126-5135
pubmed: 31760872
ACS Chem Biol. 2016 Aug 19;11(8):2275-84
pubmed: 27294372
Nat Prod Rep. 2020 Jul 1;37(7):879-892
pubmed: 31912842
Brief Bioinform. 2019 Jul 19;20(4):1160-1166
pubmed: 28968734
Antonie Van Leeuwenhoek. 2000 Dec;78(3-4):287-95
pubmed: 11386351
J Biomol NMR. 2015 Sep;63(1):77-83
pubmed: 26195077
Sci Adv. 2018 Apr 11;4(4):eaar5459
pubmed: 29651464

Auteurs

Kyle L Dunbar (KL)

Hexagon Bio, Menlo Park, CA 94025.

Bruno Perlatti (B)

Hexagon Bio, Menlo Park, CA 94025.

Nicholas Liu (N)

Hexagon Bio, Menlo Park, CA 94025.

Amber Cornelius (A)

Hexagon Bio, Menlo Park, CA 94025.

Daniel Mummau (D)

Hexagon Bio, Menlo Park, CA 94025.

Yi-Ming Chiang (YM)

Hexagon Bio, Menlo Park, CA 94025.

Lawrence Hon (L)

Hexagon Bio, Menlo Park, CA 94025.

Monika Nimavat (M)

Hexagon Bio, Menlo Park, CA 94025.

Jason Pallas (J)

Hexagon Bio, Menlo Park, CA 94025.

Sina Kordes (S)

Proteros Biostructures GmbH, Planegg D-82152, Germany.

Ho Leung Ng (HL)

Hexagon Bio, Menlo Park, CA 94025.

Colin J B Harvey (CJB)

Hexagon Bio, Menlo Park, CA 94025.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH